Fat-Derived Molecules Tied to Placebo Pain Relief When Endorphins Run Low

A bioRxiv preprint in 48 healthy adults links placebo analgesia to rising endocannabinoid metabolites, but mainly in people whose opioid response is weak, giving pain researchers a second pathway to test alongside endorphins.

A preprint posted to bioRxiv reports that placebo pain relief in 48 healthy adults tracked rises in a family of circulating fat-derived signaling molecules known as FAAH substrates, and that the link was strongest in participants whose beta-endorphin response was weak. The finding addresses a long-standing gap in placebo research: naloxone, a drug that blocks opioid receptors, has never fully abolished placebo analgesia in prior studies, implying that some non-opioid system was doing part of the work.

In the study, researchers drew blood at baseline and again before and after a validated placebo pain paradigm and a control condition, measuring circulating endocannabinoid ligands together with beta-endorphin. Participants who reported the most pain reduction under placebo showed the largest increases in a combined measure of three endocannabinoid-related molecules broken down by the enzyme FAAH: anandamide, palmitoylethanolamide and oleoylethanolamide. Neither 2-arachidonoylglycerol, a separate endocannabinoid, nor beta-endorphin measured alone tracked with how much pain relief someone felt.

The researchers report that beta-endorphin moderated the relationship: the rise in FAAH substrates predicted pain reduction mainly when beta-endorphin levels were low, according to the preprint. The authors describe this as evidence that the endocannabinoid and opioid systems interact in a state-dependent way rather than operating independently. The idea that endocannabinoid signaling shapes placebo responses is not entirely new: a 2013 study in Molecular Psychiatry had already linked a common variant of the FAAH gene to stronger placebo analgesia and mood effects, though that work used genetics rather than blood measurements.

The new work has not yet been peer reviewed, and its authors studied healthy volunteers undergoing a brief experimental pain task, not people with chronic pain or any diagnosed condition. The design is observational: it reports an association between blood molecule levels and reported pain relief, not proof that one causes the other, and it does not test, recommend or evaluate any drug, supplement or dose.

The authors frame the result as a candidate second neurochemical pathway for placebo analgesia, one they say merits testing in larger and more diverse groups before anyone draws clinical conclusions from it.